Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma

Immunotherapy has emerged as a promising therapeutic option for advanced or unresectable hepatocellular carcinoma (HCC). However, survival remains poor with only a subset of patients deriving benefit. This trial investigated the safety and efficacy of stereotactic body radiation therapy (SBRT) with immunotherapy in HCC.

Source: International Journal of Radiation Oncology * Biology * Physics - September 12, 2022 Category: Radiology Authors: Aditya Juloori, Rohan R. Katipally, Jeffrey M. Lemons, Anurag K. Singh, Renuka Iyer, Jared R. Robbins, Ben George, William A. Hall, Sean P. Pitroda, Fauzia Arif, John Fung, Anjana Pillai, Chih-Yi Liao, Manish Sharma, Stanley L. Liauw Tags: CLINICAL INVESTIGATION Source Type: research